azd8205
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Oct 18, 2021 (NCT05123482)
Timeline
Indications
Mechanism of action
inhibitor - VTCN1
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314766 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07044336 | Phase 3 | Aug 1, 2025 | AstraZeneca, Icahn School of Medicine at Mount Sinai, Medical University Innsbruck |
| NCT05123482 | Phase 1/Phase 2 (Phase 2) | Oct 18, 2021 | AstraZeneca |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 2 | 2 | 2 | 2021 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Medical University Innsbruck | Academic/Hospital | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1